DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The report "Electro-Oxidation Market by Type (Direct Electro-Oxidation, Indirect Electro-Oxidation), Electrode Material (Boron-Doped Diamond (BBD), Lead...
DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The report "Electro-Oxidation Market by Type (Direct Electro-Oxidation, Indirect Electro-Oxidation), Electrode Material (Boron-Doped Diamond (BBD), Lead...
Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.
Alzheimer's disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing...
Veteran-led innovation introduces a multi-functional air filter system using Conducted Direct Current (CDC) to address environmental and wellness concerns
Veteran-led innovation introduces a multi-functional air filter system using Conducted Direct Current (CDC) to address environmental and wellness concerns